







We claim:

1. A compound of the general formula (I),



or a stereoisomer, a pharmaceutically acceptable salt thereof,
wherein,

R₁ is alkyl or cycloalkyl;



R₅ is fluoro, hydroxy, alkoxy or OH;

X is hydrogen, hydroxy or halogen;


“n” is an integer ranging from 0 to 1, both inclusive;

“m” is an integer ranging from 1 to 4, both inclusive;

“p” is an integer ranging from 0 to 3, both inclusive.

2. The compound as claimed in claim 1, wherein the compound is selected from:






(a) a compound of formula (Ia):



or a stereoisomer, a pharmaceutically acceptable salt thereof,

wherein,

R₁ is alkyl or cycloalkyl;



R₅ is fluoro, hydroxy or alkoxy;


X is hydrogen, hydroxy or halogen;

“n” is an integer ranging from 0 to 1, both inclusive;

“m” is an integer ranging from 1 to 4, both inclusive;




“p” is an integer ranging from 0 to 3, both inclusive;

(b) a compound of formula **(Ib)**:



or a stereoisomer, a pharmaceutically acceptable salt thereof,
wherein,


R₁ is alkyl or cycloalkyl;



X is hydroxy;





“n” is an integer ranging from 0 to 1, both inclusive;

(c) a compound of formula **(Ic)**:



or a stereoisomer, a pharmaceutically acceptable salt thereof,
wherein,

R₁ is alkyl;




X is hydrogen or hydroxy;

“n” is an integer ranging from 0 to 1, both inclusive;

“p” is an integer ranging from 0 to 3, both inclusive;




(d) a compound of formula (**Id**):




or a stereoisomer, a pharmaceutically acceptable salt thereof,

wherein,

R₁ is alkyl;






R_5 is fluoro, hydroxy or alkoxy;

X is hydrogen, hydroxy or halogen;




“n” is an integer ranging from 0 to 1, both inclusive;

(e) a compound of formula **(Ie)**:



or a stereoisomer, a pharmaceutically acceptable salt thereof,
wherein,

R_1 is alkyl;



R_5 is alkoxy;

X is hydrogen;

“n” is an integer ranging from 0 to 1, both inclusive;

“p” is an integer ranging from 0 to 3, both inclusive.

3. The compound according to claim 1, which is selected from the group consisting of:
N-[N-(tetrahydropyran-4-yl methyl) piperidin-4-yl methyl]-2-isopropyl-2H-indazole-7-carboxamide fumarate;

N-[N-(tetrahydropyran-4-yl methyl) piperidin-4-yl methyl]-2-ethyl-2H-indazole-7-carboxamide fumarate;

N-[N-(3-methoxy propyl)-3-aza bicyclo[3.1.0]hexane-6-yl methyl]-2-isopropyl-2H-indazole-7-carboxamide oxalate;

N-[N-(3-methoxy propyl) piperidin-4-ylmethyl]-2-ethyl-2H-indazole-7-carboxamide fumarate;

N-[N-(3-methoxy propyl)-3-aza bicyclo[3.1.0]hexane-6-yl methyl]-2-ethyl-2H-indazole-7-carboxamide oxalate;

N-[N-(3-hydroxy-2,2-dimethyl propyl) piperidin-4-ylmethyl]-2-isopropyl-2H-indazole-7-carboxamide L(+) Tartarate;

N-[N-(2-fluoroethyl) piperidin-4-yl methyl]-2-isopropyl-2H-indazole-7-carboxamide;

N-[N-benzyl morpholin-2-yl methyl]-2-isopropyl-2H-indazole-7-carboxamide fumarate;

N-[N-(tetrahydropyran-4-yl methyl) morpholine-2-yl methyl]-2-isopropyl-2H-indazole-7-carboxamide;

N-[N-(tetrahydropyran-4-yl methyl)-3-aza bicyclo[3.1.0]hexane-6-yl methyl]-2-isopropyl-2H-indazole-7-carboxamide;

N-[N-(1-hydroxy cyclopentylmethyl) piperidin-4-yl methyl]-2-isopropyl-2H-indazole-7-carboxamide L(+) tartarate;

N-[N-(tetrahydropyran-4-yl)-3-aza bicyclo[3.1.0]hexane-6-yl methyl]-2-isopropyl-2H-indazole-7-carboxamide;

N-(N-isopropyl piperidin-4-ylmethyl)-2-isopropyl-2H-indazole-7-carboxamide fumarate;

N-(N-cyclobutyl piperidin-4-yl methyl)-2-isopropyl-2H-indazole-7-carboxamide fumarate;

N-(N-cyclohexyl piperidin-4-yl methyl)-2-isopropyl-2H-indazole-7-carboxamide fumarate;

N-(N-isopropyl-3-aza bicyclo[3.1.0]hexane-6-yl methyl)-2-isopropyl-2H-indazole-7-carboxamide fumarate;

N-[N-(4-hydroxy tetrahydro pyran-4-yl methyl) piperidin-4-yl methyl]-2-isopropyl-2H-indazole-7-carboxamide fumarate;

N-[N-(tetrahydro pyran-4-yl)-3-aza bicyclo[3.1.0]hexane-6-yl methyl]-2-ethyl-2H-indazole-7-carboxamide oxalate;

N-(N-isopropyl piperidine-4-yl)-2-isopropyl-2H-indazole-7-carboxamide fumarate;

N-(N-cyclopropylmethyl piperidine-4-yl)-2-isopropyl-2H-indazole-7-carboxamide fumarate;

N-(N-cyclobutylmethyl piperidine-4-yl)-2-isopropyl-2H-indazole-7-carboxamide fumarate;

N-[N-(tetrahydropyran-4-yl methyl)-4-fluoro piperidin-4-yl methyl]-2-isopropyl-2H-indazole-7-carboxamide;

N-[N-(tetrahydrofuran-3-yl methyl) piperidin-4-yl methyl]-2-isopropyl-2H-indazole-7-carboxamide;

N-[N-(3-methoxy propyl) piperidin-4-yl methyl]-2-isopropyl-2H-indazole-7-carboxamide fumarate;

N-[N-(2-methoxy ethyl) piperidin-4-yl methyl]-2-isopropyl-2H-indazole-7-carboxamide fumarate;

N-[N-(tetrahydropyran-4-yl methyl)-4-hydroxy piperidin-4-yl methyl]-2-isopropyl-2H-indazole-7-carboxamide fumarate;

N-[N-(tetrahydropyran-4-yl)-4-hydroxy piperidin-4-yl methyl]-2-isopropyl-2H-indazole-7-carboxamide fumarate;

N-[N-(3-methoxy propyl)-4-hydroxypiperidin-4-yl methyl]-2-isopropyl-2H-indazole-7-carboxamide fumarate;

N-[N-(3-Hydroxy-3-methyl butyl) piperidin-4-yl methyl]-2-isopropyl-2H-indazole-7-carboxamide;

N-[N-(2-hydroxy-2-methyl propyl)-4-hydroxy piperidin-4-ylmethyl]-2-isopropyl-2H-indazole-7-carboxamide oxalate;

N-[N-(4-hydroxy tetrahydropyran-4-yl methyl)-4-fluoro piperidin-4-yl methyl]-2-isopropyl-2H-indazole-7-carboxamide L(+) Tartarate;

N-[N-(2-hydroxy-2-methyl propyl) piperidin-4-yl methyl]-2-isopropyl-2H-indazole-7-carboxamide L(+) Tartarate;

N-[N-(2-Methoxy-2-methyl propyl) piperidin-4-yl methyl]-2-isopropyl-2H-indazole-7-carboxamide;

N-[N-(2-fluoro-2-methyl propyl) piperidin-4-yl methyl]-2-isopropyl-2H-indazole-7-carboxamide L(+) Tartarate;

N-[N-(2-hydroxy-2-methyl propyl)-4-fluoro piperidin-4-ylmethyl]-2-isopropyl-2H-indazole-7-carboxamide L(+) Tartarate;

N-[N-(2-hydroxy-2-methyl propyl)-3-aza bicyclo[3.1.0]hexane-6-yl methyl]-2-isopropyl-2H-indazole-7-carboxamide L(+) Tartarate;

2-Isopropyl-7-{5-[1-(3-methoxy propyl) piperidin-4-yl]-[1,3,4]oxadiazol-2-yl}-2H-indazole fumarate;

2-Isopropyl-7-{5-[1-(tetrahydropyran-4-yl methyl) piperidin-4-yl]-[1,3,4]oxadiazol-2-yl}-2H-indazole fumarate;

2-Isopropyl-7-{5-[1-(tetrahydropyran-4-yl) piperidin-4-yl]-[1,3,4]oxadiazol-2-yl}-2H-indazole fumarate;

N-[N-(2-hydroxy-2-methyl propyl) piperidin-4-yl methyl]-2-isopropyl-2H-indazole-7-carboxamide Oxalate;

N-[N-(tetrahydropyran-4-yl methyl) piperidin-4-yl methyl]-2-isopropyl-2H-indazole-7-carboxamide;

N-[N-(tetrahydropyran-4-yl methyl) piperidin-4-yl methyl]-2-ethyl-2H-indazole-7-carboxamide;

N-[N-(3-methoxy propyl)-3-aza bicyclo[3.1.0]hexane-6-yl methyl]-2-isopropyl-2H-indazole-7-carboxamide;

N-[N-(3-methoxy propyl) piperidin-4-ylmethyl]-2-ethyl-2H-indazole-7-carboxamide;
 N-[N-(3-methoxy propyl)-3-aza bicyclo[3.1.0]hexane-6-yl methyl]-2-ethyl-2H-indazole-7-carboxamide;
 N-[N-(3-hydroxy-2,2-dimethyl propyl) piperidin-4-ylmethyl]-2-isopropyl-2H-indazole-7-carboxamide;
 N-[N-benzyl morpholin-2-yl methyl]-2-isopropyl-2H-indazole-7-carboxamide;
 N-[N-(1-hydroxy cyclopentylmethyl) piperidin-4-yl methyl]-2-isopropyl-2H-indazole-7-carboxamide;
 N-(N-isopropyl piperidin-4-ylmethyl)-2-isopropyl-2H-indazole-7-carboxamide;
 N-(N-cyclobutyl piperidin-4-yl methyl)-2-isopropyl-2H-indazole-7-carboxamide;
 N-(N-cyclohexyl piperidin-4-yl methyl)-2-isopropyl-2H-indazole-7-carboxamide;
 N-(N-isopropyl-3-aza bicyclo[3.1.0]hexane-6-yl methyl)-2-isopropyl-2H-indazole-7-carboxamide;
 N-[N-(4-hydroxy tetrahydro pyran-4-yl methyl) piperidin-4-yl methyl]-2-isopropyl-2H-indazole-7-carboxamide;
 N-[N-(tetrahydro pyran-4-yl)-3-aza bicyclo[3.1.0]hexane-6-yl methyl]-2-ethyl-2H-indazole-7-carboxamide;
 N-(N-isopropyl piperidine-4-yl)-2-isopropyl-2H-indazole-7-carboxamide;
 N-(N-cyclopropylmethyl piperidine-4-yl)-2-isopropyl-2H-indazole-7-carboxamide;
 N-(N-cyclobutylmethyl piperidine-4-yl)-2-isopropyl-2H-indazole-7-carboxamide;
 N-[N-(3-methoxy propyl) piperidin-4-yl methyl]-2-isopropyl-2H-indazole-7-carboxamide;
 N-[N-(2-methoxy ethyl) piperidin-4-yl methyl]-2-isopropyl-2H-indazole-7-carboxamide;
 N-[N-(tetrahydropyran-4-yl methyl)-4-hydroxy piperidin-4-yl methyl]-2-isopropyl-2H-indazole-7-carboxamide;
 N-[N-(tetrahydropyran-4-yl)-4-hydroxy piperidin-4-yl methyl]-2-isopropyl-2H-indazole-7-carboxamide;
 N-[N-(3-methoxy propyl)-4-hydroxypiperidin-4-yl methyl]-2-isopropyl-2H-indazole-7-carboxamide;
 N-[N-(2-hydroxy-2-methyl propyl)-4-hydroxy piperidin-4-ylmethyl]-2-isopropyl-2H-indazole-7-carboxamide;
 N-[N-(4-hydroxy tetrahydropyran-4-yl methyl)-4-fluoro piperidin-4-yl methyl]-2-isopropyl-2H-indazole-7-carboxamide;
 N-[N-(2-hydroxy-2-methyl propyl) piperidin-4-yl methyl]-2-isopropyl-2H-indazole-7-carboxamide;
 N-[N-(2-fluoro-2-methyl propyl) piperidin-4-yl methyl]-2-isopropyl-2H-indazole-7-carboxamide;
 N-[N-(2-hydroxy-2-methyl propyl)-4-fluoro piperidin-4-ylmethyl]-2-isopropyl-2H-indazole-7-carboxamide;

N-[N-(2-hydroxy-2-methyl propyl)-3-aza bicyclo[3.1.0]hexane-6-yl methyl]-2-isopropyl-2H-indazole-7-carboxamide;

2-Isopropyl-7-{5-[1-(3-methoxy propyl) piperidin-4-yl]-[1,3,4]oxadiazol-2-yl}-2H-indazole;

2-Isopropyl-7-{5-[1-(tetrahydropyran-4-yl methyl) piperidin-4-yl]-[1,3,4]oxadiazol-2-yl}-2H-indazole; and

2-Isopropyl-7-{5-[1-(tetrahydropyran-4-yl) piperidin-4-yl]-[1,3,4]oxadiazol-2-yl}-2H-indazole; or a stereoisomer, a pharmaceutically acceptable salt thereof.

4. A pharmaceutical composition comprising a compound according to any one of the claims 1 to 3 and pharmaceutically acceptable excipients.

5. The pharmaceutical composition according to claim 4, for use in the treatment of clinical conditions mediated through 5-HT₄ receptor agonists selected from Alzheimer's disease, schizophrenia, attention deficit hyperactivity disorder, Huntington's disease, Parkinson's disease, depression or psychiatric disorders.

6. Use of pharmaceutical composition according to claim 4 in the manufacture of medicament for the treatment of clinical conditions mediated through 5-HT₄ receptor agonists selected from Alzheimer's disease, schizophrenia, attention deficit hyperactivity disorder, Huntington's disease, Parkinson's disease, depression or psychiatric disorders.

7. The compound according to any one of the claims 1 to 3, for use in the treatment of cognitive disorders, dementia, attention deficit hyperactivity disorder, schizophrenia and pain.

8. Use of a compound according to any one of the claims 1 to 3 in the manufacture of medicament for the treatment of diseases selected from Alzheimer's disease, schizophrenia, attention deficit hyperactivity disorder, Huntington's disease, Parkinson's disease, depression or psychiatric disorders.